Patents by Inventor Dennis A. Carson

Dennis A. Carson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5028594
    Abstract: Hematopoietic cells are selectively eliminated by cytotoxic agents which rely upon light activation. The cytotoxic agents are joined to ligands, particularly sugars, specific for myeloid monocyte and lymphocytic lineages. Further specificity can be achieved by limiting the light target. The method and compositions find particular use in organ transplants and arthritis.
    Type: Grant
    Filed: December 27, 1988
    Date of Patent: July 2, 1991
    Assignee: Naxcor
    Inventor: Dennis A. Carson
  • Patent number: 4997926
    Abstract: Adenine deaminase-stable adenine derivatives bonded 9,1' to a furanosidyl ring containing a 5'-hydroxyl group are described. These compounds are useful in a method of inhibiting replication of reverse transcriptase-dependent viruses.
    Type: Grant
    Filed: November 18, 1987
    Date of Patent: March 5, 1991
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Thomasz Haertle, Dennis A. Carson
  • Patent number: 4683295
    Abstract: A method is discussed for the production of anti-receptor antibodies and to the detection and isolation of naturally occurring anti-receptor antibodies in animals and humans. The anti-receptor antibodies can be isolated from polyvalent anti-receptor antisera by immunodepletion of anti-immunoglobulin antibodies or by a single affinity purification step using antibody raised to an antigen recognized by the receptor.
    Type: Grant
    Filed: May 24, 1984
    Date of Patent: July 28, 1987
    Assignee: Scripps Clinic and Research Foundation
    Inventor: Dennis A. Carson
  • Patent number: 4654419
    Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R.sup.1 -Gly-R.sup.2 -Gly-, wherein R.sup.1 and R.sup.2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R.sup.1 and R.sup.2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.
    Type: Grant
    Filed: August 8, 1984
    Date of Patent: March 31, 1987
    Assignee: Scripps Clinic and Research Foundation
    Inventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten
  • Patent number: 4387161
    Abstract: Detection of mycoplasma infection in an animal cell culture is accomplished by growing animal cells from a culture in a growth medium in the presence of 6-methylpurine deoxyriboside and determining whether animal cells are killed.
    Type: Grant
    Filed: July 16, 1981
    Date of Patent: June 7, 1983
    Assignee: Institute for Medical Research
    Inventors: Gerard J. McGarrity, Dennis A. Carson